Superworth

Bruker price to free cash flow BRKR

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026
93.4×
10-year median
48.2×
Against its 10-year history
91st
percentile: 0 is its lowest day, 100 its highest
10-year range
19.1× to 186×
Peer median
26.4×

Bruker's price to free cash flow is 93.4× as of Oct 23, 2026.

That is above its ten-year median of 48.2×, higher than on 91% of days in the last ten years.

Over that time it ranged from 19.1× in Oct 2016 to 186× in Jul 2026.

The median for 10 diagnostics and research stocks of a similar size is 26.4×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far93.4×86.7×186×
2025120×30.8×120×
202456.5×39.7×63.6×
202349.3×38.8×93.2×
202284.8×38.6×86.8×
202150.0×34.2×57.0×
202049.1×36.7×57.2×
201954.4×26.9×62.3×
201826.9×24.4×56.5×
201753.9×23.2×55.5×
201622.3×19.1×36.8×
201534.2×22.1×43.5×
201423.5×18.9×93.0×
201383.7×38.8×99.4×
201236.5×19.3×79.5×

Against its peers

Companies in Medical - Diagnostics & Research nearest Bruker's size, closest first, today.

CompanyPrice to free cash flow
BRKRBruker93.4×
CAICaris Life Sciences73.0×
BIOBio-Rad Laboratories28.0×
LNTHLantheus16.8×
BLLNBillionToOne153×
RVTYRevvity31.7×
MEDPMedpace26.4×
VCYTVeracyte23.2×
CDNACareDxn/m
LHLabcorp23.1×
DGXQuest Diagnostics19.8×
Peer median26.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Bruker

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.